The Department of Defense has given Codagenix Inc., a clinical-stage synthetic biology company with a platform for rational virus design for viral vaccines and immuno-oncology therapeutics, a $4.4 million award to advance the development of CodaVax-DENV, which is the next-generation dengue vaccine candidate.
As per the recent report by PR newswire, the three-year contract, made possible by the Joint Warfighter Medical Research Program (JWMRP), will pay for manufacturing and preclinical research that enable the development of Investigational New Drugs (INDs) in order to submit IND applications and conduct Phase 1 clinical trials.
According to J. Robert Coleman, Ph.D., the co-founder and CEO of Codagenix said, “We are honored that the Department of Defense chose us for this honor. The funding enables us to develop CodaVax-DENV closer to the clinic and evaluate its potential as a secure and reliable choice for safeguarding our military personnel and high-risk populations around the world,” further added, “We are at a perfect place to solve the usual challenges of dengue vaccine development, and we look ahead to contributing to the completion of general protection against this persistent illness.”
Codagenix is a biotechnology firm working on the development of vaccines and viral therapies. The company’s ground-breaking technology is working to provide remedies to combat our greatest dangers in infectious disease, animal health, and cancer.
As per the report, over 2.4 billion people worldwide reside in dengue-affected areas. Dengue is a viral infection caused by mosquitoes and is becoming a major concern throughout the world as there are no vaccines or particular therapies available for adults. This disease is becoming a serious threat to the natives of Latin America and Asian Nations, having a spread rate of roughly around 70%.
The competing strategies for developing a dengue vaccine have generally been based on the previous strain of the virus in order to balance the research while creating the vaccine. Through selective codon deoptimization, Codagenix’s vaccine design platform has made it possible to precisely and logically attenuate modern serotypes of all four dengue virus strains. By using this strategy, Codagenix can rationally balance each of the four viral serotypes to create a vaccine that is both secure and highly immunogenic.